Mast Therapeutics Inc (MSTX) 0.58 $MSTX
Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
PR Newswire - Mon Sep 08, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution for the treatment of pulmonary arterial hypertension (PAH). Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals, Inc. earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance (PVR). In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
PR Newswire - Tue Sep 02, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman and Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the Holmes II Salon at The New York Palace Hotel in New York.
Mast Therapeutics Announces Management Change
PR Newswire - Fri Aug 29, 3:05PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical Officer and Senior Vice President, will be leaving the Company, for personal reasons, in mid-September. Edwin L. Parsley, D.O., the Chief Medical Officer of Aires Pharmaceuticals, which Mast acquired earlier this year, will assume Dr. Vetticaden's former responsibilities as the Company's interim Chief Medical Officer. Dr. Parsley previously was with Pfizer, where he oversaw clinical trials for Revatio® (sildenafil). He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine. Dr. Parsley has been actively engaged with the Company since Aires was acquired by Mast in February 2014.
Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results
PR Newswire - Mon Aug 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided a corporate update and reported financial results for the quarter ended June 30, 2014.
Technical Recap on Biotech Equities -- CytRx, AVEO Pharma, Mast Therapeutics, Immunomedics, and Dynavax Technologies
PR Newswire - Fri Aug 08, 8:00AM CDT
On Thursday, August 07, 2014, the NASDAQ Composite ended at 4,334.97, down 0.46%, the Dow Jones Industrial Average finished the day 0.46% lower at 16,368.27, and the S&P 500 closed at 1,909.57, down 0.56%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 692.10, down 1.19%, and the index has declined 3.33% in the last one month. Investor-Edge has initiated coverage on the following equities: CytRx Corporation (NASDAQ: CYTR), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Mast Therapeutics Inc. (NYSE MKT: MSTX), Immunomedics Inc. (NASDAQ: IMMU), and Dynavax Technologies Corporation (NASDAQ: DVAX). Free research on these five companies can be accessed at:
Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
PR Newswire - Thu Aug 07, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 2:30 p.m. Eastern time at The InterContinental Hotel in Boston.
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Fri Jun 20, 7:27AM CDT
These biotech stocks trading for under $10 are starting to push higher into breakout territory.
Mast Announces names Dr Howard C Dittrich to board
M2 - Fri Jun 20, 4:03AM CDT
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) revealed on Thursday the addition of Howard C Dittrich MD FACC, to its board of directors.
Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
PR Newswire - Thu Jun 19, 3:15PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development.
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
PR Newswire - Mon Jun 16, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device.
A Small-Cap Biotech Stock With Promise: MSTX
at The Street - Wed Mar 26, 1:55PM CDT
This small-cap biotech stock could be setting up for a great buying opportunity here following the massive selloff in the space.
Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Wed Mar 26, 7:15AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013.
Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
PR Newswire - Wed Mar 26, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion of a limb, typically in the legs, that often threatens viability of the limb. Patients presenting with ALI have a poor short-term outlook, with 30-day amputation rates as high as 30% and a mortality rate around 15%. MST-188 for the treatment of ALI has been granted orphan drug designation by the U.S. Food and Drug Administration.
Active Stocks Coverage -- Research on Starbucks, Gerdau, Mast Therapeutics and Cia de Saneamento Basico do Estado
PR Newswire - Fri Mar 21, 9:28AM CDT
The trading session on Thursday, March 20, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based with 9 of 10 sectors ended the session in positive. Investor-Edge looks at some of the equities which traded the most shares during the session. These include FullStarbucks Corp. (NASDAQ: SBUX), Gerdau S.A. (NYSE: GGB), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Cia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS). Free technical research on SBUX, GGB, MSTX and SBS can be downloaded upon signing up at:
Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
PR Newswire - Tue Mar 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug products containing non-purified poloxamers should not be substituted for MST-188 and that confusion between the two could have serious toxicity consequences.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX" , a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial."
Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
PR Newswire - Mon Sep 08, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported top-line results from a Phase 2 study of AIR001 (sodium nitrite) inhalation solution for the treatment of pulmonary arterial hypertension (PAH). Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals, Inc. earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance (PVR). In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th
PR Newswire - Tue Sep 02, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman and Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the Holmes II Salon at The New York Palace Hotel in New York.
Mast Therapeutics Announces Management Change
PR Newswire - Fri Aug 29, 3:05PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX), an emerging biopharmaceutical company, announced today that Santosh Vetticaden, Chief Medical Officer and Senior Vice President, will be leaving the Company, for personal reasons, in mid-September. Edwin L. Parsley, D.O., the Chief Medical Officer of Aires Pharmaceuticals, which Mast acquired earlier this year, will assume Dr. Vetticaden's former responsibilities as the Company's interim Chief Medical Officer. Dr. Parsley previously was with Pfizer, where he oversaw clinical trials for Revatio® (sildenafil). He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine. Dr. Parsley has been actively engaged with the Company since Aires was acquired by Mast in February 2014.
Mast Therapeutics Provides Corporate Update And Reports Second Quarter 2014 Financial Results
PR Newswire - Mon Aug 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today provided a corporate update and reported financial results for the quarter ended June 30, 2014.
Technical Recap on Biotech Equities -- CytRx, AVEO Pharma, Mast Therapeutics, Immunomedics, and Dynavax Technologies
PR Newswire - Fri Aug 08, 8:00AM CDT
On Thursday, August 07, 2014, the NASDAQ Composite ended at 4,334.97, down 0.46%, the Dow Jones Industrial Average finished the day 0.46% lower at 16,368.27, and the S&P 500 closed at 1,909.57, down 0.56%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 692.10, down 1.19%, and the index has declined 3.33% in the last one month. Investor-Edge has initiated coverage on the following equities: CytRx Corporation (NASDAQ: CYTR), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Mast Therapeutics Inc. (NYSE MKT: MSTX), Immunomedics Inc. (NASDAQ: IMMU), and Dynavax Technologies Corporation (NASDAQ: DVAX). Free research on these five companies can be accessed at:
Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
PR Newswire - Thu Aug 07, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Canaccord Genuity 34th Annual Growth Conference on Thursday, August 14, 2014 at 2:30 p.m. Eastern time at The InterContinental Hotel in Boston.
4 Biotech Stocks Under $10 to Watch for Breakout Trades
at The Street - Fri Jun 20, 7:27AM CDT
These biotech stocks trading for under $10 are starting to push higher into breakout territory.
Mast Announces names Dr Howard C Dittrich to board
M2 - Fri Jun 20, 4:03AM CDT
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) revealed on Thursday the addition of Howard C Dittrich MD FACC, to its board of directors.
Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
PR Newswire - Thu Jun 19, 3:15PM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development.
Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
PR Newswire - Mon Jun 16, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device.
A Small-Cap Biotech Stock With Promise: MSTX
at The Street - Wed Mar 26, 1:55PM CDT
This small-cap biotech stock could be setting up for a great buying opportunity here following the massive selloff in the space.
Mast Therapeutics Reports Fourth Quarter And Full Year 2013 Financial Results
PR Newswire - Wed Mar 26, 7:15AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today reported financial results for the fourth quarter and year ended December 31, 2013.
Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia
PR Newswire - Wed Mar 26, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that it has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia. Acute limb ischemia (ALI), an acute complication of peripheral arterial disease, describes a sudden decrease in perfusion of a limb, typically in the legs, that often threatens viability of the limb. Patients presenting with ALI have a poor short-term outlook, with 30-day amputation rates as high as 30% and a mortality rate around 15%. MST-188 for the treatment of ALI has been granted orphan drug designation by the U.S. Food and Drug Administration.
Active Stocks Coverage -- Research on Starbucks, Gerdau, Mast Therapeutics and Cia de Saneamento Basico do Estado
PR Newswire - Fri Mar 21, 9:28AM CDT
The trading session on Thursday, March 20, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,331.05, up 0.67% and the NASDAQ Composite closed at 4,319.29, up 0.27%. The S&P 500 finished the session 0.60% higher at 1,872.01. The gains were broad based with 9 of 10 sectors ended the session in positive. Investor-Edge looks at some of the equities which traded the most shares during the session. These include FullStarbucks Corp. (NASDAQ: SBUX), Gerdau S.A. (NYSE: GGB), Mast Therapeutics Inc. (NYSE MKT: MSTX) and Cia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS). Free technical research on SBUX, GGB, MSTX and SBS can be downloaded upon signing up at:
Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council
PR Newswire - Tue Mar 11, 7:00AM CDT
Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today that the United States Adopted Names (USAN) Council has selected "vepoloxamer" as the unique non-proprietary (generic) name for the active pharmaceutical ingredient (API) in MST-188, the Company's lead product candidate. Mast sought a unique name for its API to clearly identify it as different from non-purified poloxamers. In support of its application, the Company argued that drug products containing non-purified poloxamers should not be substituted for MST-188 and that confusion between the two could have serious toxicity consequences.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. 5 Stocks Under $10 Set to Soar
at The Street - Thu Mar 06, 12:39PM CST
These under-$10 stocks look ready to trade higher from current levels.
Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25
Marketwire - Fri Feb 28, 8:00AM CST
Vista Partners announced today that it has updated coverage on Mast Therapeutics Inc. (NYSE MKT: MSTX) ("MSTX"
, a publicly traded biopharmaceutical company headquartered in San Diego, CA; and maintains its twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "There has been considerable partnership and M&A activity for companies working on Sickle Cell Disease. On Sept. 19th, 2012, Selexys Pharmaceuticals, Corp. entered into an agreement with Novartis Pharmaceuticals, the agreement with Novartis could reach up to $665 million. In October 2011, Pfizer signed a licensing deal with U.S. firm GlycoMimetics which may be worth up to $340 million, including an upfront payment as well as development, regulatory, and commercial milestones, plus royalties." Mr. Silver, concludes, "GlycoMimetics (NASDAQ: GLYC), the first biotech IPO of 2014, currently trades at a market cap of around $225M whereas MSTX is around $85M. GlycoMimetics has only completed a Phase 2 trial whereas MSTX is actively enrolling patients in a Phase 3 trial." Mast Therapeutics acquires Aires Pharmaceuticals in all-stock transaction
M2 - Fri Feb 28, 3:43AM CST
Biopharmaceutical company Mast Therapeutics (NYSE MKT:MSTX) disclosed on Thursday the completion of the acquisition of Aires Pharmaceuticals in an all-stock transaction.
Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc.
PR Newswire - Thu Feb 27, 1:18PM CST
Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has completed its acquisition of Aires Pharmaceuticals, Inc. Aires' lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the U.S. and European Union for the treatment of pulmonary arterial hypertension.
